CA3248625A1 - Intravenous formulation containing istaroxime for the treatment of pre-cardiogenic shock and cardiac shock - Google Patents

Intravenous formulation containing istaroxime for the treatment of pre-cardiogenic shock and cardiac shock

Info

Publication number
CA3248625A1
CA3248625A1 CA3248625A CA3248625A CA3248625A1 CA 3248625 A1 CA3248625 A1 CA 3248625A1 CA 3248625 A CA3248625 A CA 3248625A CA 3248625 A CA3248625 A CA 3248625A CA 3248625 A1 CA3248625 A1 CA 3248625A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
individual
istaroxime
blood pressure
systolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3248625A
Other languages
English (en)
French (fr)
Inventor
Steven SIMONSON
Original Assignee
Windtree Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Windtree Therapeutics Inc filed Critical Windtree Therapeutics Inc
Publication of CA3248625A1 publication Critical patent/CA3248625A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3248625A 2022-04-20 2023-04-18 Intravenous formulation containing istaroxime for the treatment of pre-cardiogenic shock and cardiac shock Pending CA3248625A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263332909P 2022-04-20 2022-04-20
US63/332,909 2022-04-20
PCT/US2023/018998 WO2023205183A1 (en) 2022-04-20 2023-04-18 Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock

Publications (1)

Publication Number Publication Date
CA3248625A1 true CA3248625A1 (en) 2023-10-26

Family

ID=86331896

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3248625A Pending CA3248625A1 (en) 2022-04-20 2023-04-18 Intravenous formulation containing istaroxime for the treatment of pre-cardiogenic shock and cardiac shock

Country Status (9)

Country Link
EP (1) EP4511040A1 (enExample)
JP (1) JP2025513337A (enExample)
KR (1) KR20250005343A (enExample)
CN (1) CN119156218A (enExample)
AU (1) AU2023256547A1 (enExample)
CA (1) CA3248625A1 (enExample)
IL (1) IL316164A (enExample)
MX (1) MX2024012948A (enExample)
WO (1) WO2023205183A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025128432A1 (en) * 2023-12-11 2025-06-19 Windtree Therapeutics, Inc. Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1079807A (en) 1912-09-25 1913-11-25 Jonathan S Snyder Coat-closure.
NL95803C (enExample) 1953-12-31 1900-01-01
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US5874268A (en) 1996-09-23 1999-02-23 Duke University Method of introducing exogenous compounds into cells by electroporation and apparatus for same
CN1261791A (zh) 1997-07-02 2000-08-02 Sdg有限公司 诊断或治疗用途的靶向脂质体构建物
SE9704076D0 (sv) 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilisation of cell structures and use thereof
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
KR20060123384A (ko) 2003-12-24 2006-12-01 가부시키가이샤 엘티티 바이오파마 약물을 함유하는 나노 입자 및 그 제조 방법, 그리고 당해나노 입자로 이루어지는 비경구 투여용 제제
US20070082042A1 (en) 2004-08-06 2007-04-12 Deok-Hoon Park Multiple-layered liposome and preparation method thereof
EP1812074B1 (en) 2004-10-18 2010-12-29 Nitto Denko Corporation Intracellular peptide delivery
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
CN103315968B (zh) 2013-06-26 2015-04-01 中国生命药物治疗有限公司 一种注射用粉针剂及其制备方法
CN112118846B (zh) 2019-03-05 2024-04-16 风树疗法公司 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂

Also Published As

Publication number Publication date
MX2024012948A (es) 2024-11-08
EP4511040A1 (en) 2025-02-26
JP2025513337A (ja) 2025-04-24
WO2023205183A1 (en) 2023-10-26
AU2023256547A1 (en) 2024-11-28
KR20250005343A (ko) 2025-01-09
IL316164A (en) 2024-12-01
CN119156218A (zh) 2024-12-17

Similar Documents

Publication Publication Date Title
US10973836B2 (en) Methods of treating heart failure with reduced ejection fraction
US20080032933A1 (en) Type V Phosphodiesterase Inhibitors and Natriuretic Polypeptides
US11583540B2 (en) Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
US20230277496A1 (en) Methods for treating cardiovascular diseases
Kasama et al. Effects of perindopril on cardiac sympathetic nerve activity in patients with congestive heart failure: comparison with enalapril
US20240293426A1 (en) Intravenous istaroxime for the treatment of acute heart failure
EP4511040A1 (en) Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock
Almeida et al. Three-vessel myocardial bridging: a possible cause of myocardial stunning
Laufs et al. Clinical trial updates and hotline sessions presented at the Scientific Session 2007 of the American Heart Association
WO2025128432A1 (en) Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia
CA3130261C (en) Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)
FOWKES et al. Acute coronary syndromes (ACS)
Sims et al. Acute Decompensated Heart Failure
Prado et al. Beyond Childhood: Percutaneous Closure of an Aortopulmonary Window with Severe Pulmonary Hypertension in an Adult Woman–A Case Report
WO2026093586A1 (en) Combination of a aldosterone synthase inhibitor (asi) and a sodium-glucose co-transporter 2 inhibitor (sglt2i) for use in methods of reducing the risk of cardiovascular and heart failure events in a subject
Akar et al. Can SGLT2 Inhibitors be a Good Option in the Management of Resistant Hypertension in Diabetic Hypertensive Patients?
BR122025016233A2 (pt) Usos de composições farmacêuticas que compreendem um inibidor do sglt2
Park Pharmacotherapeutic options for pulmonary arterial hypertension

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241011

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241106

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241106

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241120

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250407

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260323

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260323